Clinical Trial Q&A

Can Brimonidine Reduce GA Progression?

Phase IIA trial shows potential of its neuroprotective properties for retinal disease.

Drugability of the Suprachoroidal Space

Phase II trial shows Clearside’s CLS-TA safe and effective in noninfectious uveitis.

APL-2’s Role in Blocking the GA Cascade

By inhibiting complement factor C3, Apellis bets it can prevent inflammation in advanced dry AMD

SPK-RPE65 Gene ‘Augmentation’

This biological agent targets mutations in genes that mediate visual transduction.

AKB-9778 as an Adjunct to Anti-VEGF

A deeper dive into how this Tie-2 activator stabilizes the retinal vasculature.

Impact of the OHR-102 IMPACT Data

A closer look at combination therapy and CNV.

A Quick Look at CHROMA, SPECTRI

Lead investigator provides details on parallel trials of lampalizumab.